Eradicating Helicobacter pylori to Safeguard Skeletal Integrity: Unveiling a Sex-Specific Dimension of Bone Health Authors: Hyuk Lee Published: 2026 In addition to its best-known involvement in gastrointestinal diseases, Helicobacter pylori infection is linked to various extragastric manifestations.1 Researchers are increasingly interested in the role of H. pylori in osteoporosis. Although epidemiological studies indicate a 12% to 40% higher risk for reduced bone density and osteoporosis in individuals with H. pylori infection, previous meta-analyses have yielded inconsistent results, reflecting the considerable heterogeneity across studies.2-4 Cross-sectional studies have demonstrated a correlation between H. pylori and bone loss, especially among older women; however, these results do not establish temporal causation at this time.5 There is currently a paucity of clinical evidence regarding the preventive efficacy of eradication therapy. Most existing data are limited by residual confounding and the lack of long-term follow-up, thereby leaving a critical gap in our understanding of whether clearing the infection actually leads to long-term prevention of bone loss. As such, there is an urgent need for prospective, intervention-focused studies to elucidate the effects of H. pylori eradication on the development of osteoporosis among a variety of demographic groups. In this issue of Gut and Liver, Kim et al.6 report a prospective cohort study including 20 years of follow-up that provides a longitudinal analysis of the effects of H. pylori eradication on osteoporosis. Their study included 730 subjects who underwent successful H. pylori eradication and 116 in a state of persistent infection. During the follow-up period, there were 179 cases of osteoporosis among the eradication group (24.5%) and 40 among the non-eradication group (34.5%), corresponding to an absolute difference of approximately 10%. In time-to-event analysis, persistent infection was associated with an increased osteoporosis risk compared with the eradication group (hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.13 to 2.28). In the same model, female sex (HR, 3.12; 95% CI, 1.93 to 5.05) and older age (per-year HR, 1.08; 95% CI, 1.06 to 1.10) were identified as independent risk factors. In subgroup analysis, the protective effects of H. pylori eradication were especially notable among women aged 50 years or older; however, there was no clear association among men. These results consistently show higher osteoporosis incidence and risk among individuals with persistent H. pylori infection compared with those who achieved eradication. In addition to the main findings described above, this study introduced a significant conceptual shift by redefining H. pylori eradication from static exposure to an adjustable, temporally dynamic determinant. Stratification by confirmed eradication status enabled a direct comparison between eradication and persistent infection, increasing clinical interpretability and ensuring that the definition of exposure is consistent with actual decision-making scenarios. The prospective design of the study and its long-term follow-up period strengthened its temporal validity, and time-to-event modeling enabled a precise estimation of both cumulative incidence and hazard trajectory. Methodologically, this study demonstrated analytical rigor through comprehensive multivariable adjustments for demographic, metabolic, and lifestyle-related factors, and the results are reinforced through sensitivity analysis to exclude the effects of pharmacological factors on bone metabolism. The consistency of these results across all stratification analyses further emphasizes the stability of the observed associations. Of note, consistent with findings from another cohort study linking H. pylori infection to subsequent osteoporosis risk, the sex-specific effects, in which the risk of osteoporosis decreased more after H. pylori eradication in women 50 years or older, provided some biologically and clinically significant insights.7 In post-menopausal women, bone remodeling becomes skewed towards resorption owing to estrogen deficiency, making this population even more susceptible to bone resorption stimuli. In this context, chronic systemic inflammation caused by H. pylori and mediated by cytokines such as interleukin-6 and tumor necrosis factor alpha can increase osteoclast activity and accelerate bone loss, while infection-related atrophic gastritis and hypochlorhydria can further exacerbate skeletal vulnerability by impairing calcium absorption.4 Host-related factors, including genetic polymorphisms, that affect the inflammatory response also contribute to this sex-dependent vulnerability. These mechanisms, therefore, support the interpretation that H. pylori eradication might have greater skeletal benefits among menopausal women, in particular. These results suggest that clinically, the preventive value of H. pylori eradication may differ depending on the underlying risk, with post-menopausal women noted as a subgroup that might benefit more from such intervention. These sex-specific indications support more personalized approaches in the reduction of osteoporosis risk and add a clinically feasible target. There are additional considerations that should be addressed. The non-random distribution of eradication status raised the possibility of residual confounders related to healthcare utilization, treatment adherence, and other clinical factors. There is also a risk of confounding by indication, whereby individuals who underwent H. pylori eradication therapy might differ in their fundamental health behaviors or clinical profiles. Owing to the nature of relatively well-defined clinical cohorts, generalization to broader populations may be limited. The selection of osteoporosis onset as the primary endpoint may not fully capture longitudinal changes in bone density or fracture risk. Variability in the host response and microbial characteristics was not comprehensively addressed, which might have contributed to the heterogeneity of the overall risk. The quasi-interventional framework used in this study offered conceptual advantages; however, in order to elucidate causation and refine clinical applicability, further studies with a structured intervention design including more diverse populations are needed. Taken together, the results of the study by Kim et al.6 reinforced a consistent association between H. pylori infection and osteoporosis and expounded upon the existing paradigm by demonstrating the potential for risk correction via H. pylori eradication. This study established H. pylori eradication as a feasible strategy that may contribute not only to the treatment of gastrointestinal disease but also to the long-term maintenance of skeletal health. Footnotes CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported. REFERENCES